source
- Boston biotech seed funding drops 40% as investors favor later-stage firmsBoston remains the world’s largest biotech hub, but early‑stage startups are feeling a sharp squeeze in capital. The average seed round for a pre‑clinical company in Massachusetts fell to $4.65 mi…
- Enveda Biosciences raises $311 million in Series E to accelerate nature-derived drug developmentEnveda Biosciences announced a $311 million Series E financing round, adding to the more than $500 million it has raised in previous rounds. The new capital follows a $130 million Series C in Nove…